$213.57
+1.8%STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
Strong gross margins indicate healthy pricing and efficient production or service delivery.
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Strong net margins indicate efficient operations and favorable tax/interest management.
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
Room for improvement: Moderate profitability with opportunities to enhance margins through better cost management or pricing strategy.
STE โข NYSE
| STERIS plc Income Statement | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 | Mar 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
5.9B | 5.5B | 5.1B | 4.5B | 4.2B | 3.1B | 3B | 2.8B | 2.6B | 2.6B | 2.2B | 1.9B | 1.6B | 1.5B | 1.4B | 1.2B | 1.3B | 1.3B | 1.3B | 1.2B | |
GROSS PROFIT | ||||||||||||||||||||
(3.3B) | (3.1B) | (2.9B) | (2.6B) | (2.3B) | (1.8B) | (1.7B) | (1.6B) | (1.5B) | (1.6B) | (1.3B) | (1.1B) | (972.6M) | (880.6M) | (838.3M) | (761.3M) | (718.6M) | (771.8M) | (741.1M) | (692.6M) | |
2.6B | 2.4B | 2.2B | 2B | 1.9B | 1.3B | 1.3B | 1.2B | 1.1B | 1B | 895.5M | 774.3M | 649.6M | 621.3M | 568.5M | 446.2M | 539.2M | 526.7M | 524M | 504.8M | |
OPERATING INCOME | ||||||||||||||||||||
(1.5B) | (1.5B) | (1.4B) | (1.2B) | (1.4B) | (794.7M) | (783M) | (764M) | (692.9M) | (800M) | (682.6M) | (547.1M) | (442.8M) | (378.4M) | (346.1M) | (361M) | (335.5M) | (351.3M) | (400.4M) | (367.1M) | |
(1.4B) | (1.3B) | (1.3B) | (1.1B) | (1.3B) | (731.3M) | (716.7M) | (669.9M) | (632M) | (682M) | (626.7M) | (493.3M) | (381M) | (337.7M) | (309.6M) | (325.5M) | (296.6M) | (315M) | (348M) | (326.9M) | |
(112.9M) | (107.6M) | (103.7M) | (98.5M) | (86.7M) | (66.3M) | (65.5M) | (63M) | (60.8M) | (59.4M) | (56.7M) | (54.1M) | (48.6M) | (41.3M) | (36M) | (34.3M) | (34M) | (32.8M) | (36.9M) | (33.6M) | |
1.1B | 866.6M | 836.1M | 791.1M | 477.8M | 548.4M | 537M | 411M | 399.9M | 226.2M | 212.9M | 227.2M | 206.8M | 242.8M | 222.3M | 85.2M | 203.7M | 175.4M | 123.5M | 137.7M | |
PRE-TAX INCOME | ||||||||||||||||||||
(60.7M) | (86.3M) | (144.4M) | (110.8M) | (89.5M) | (37.2M) | (40.3M) | (45M) | (50.6M) | (44.5M) | (42.7M) | (19.2M) | (18.8M) | (15.7M) | (12.1M) | (12M) | (13.2M) | (10.6M) | (0.0) | (0.0) | |
-60.7M | -77.9M | -133.3M | -110.8M | -83.2M | -30.8M | -38.3M | -42M | -44.9M | -41.6M | -41M | -18.4M | -18.4M | -15.7M | -11.2M | -11.4M | -11.9M | -9M | 0.0 | 0.0 | |
(4.1M) | (94.2M) | (26M) | (485K) | (48K) | -2.9M | (673K) | (31M) | (103K) | (58.6M) | -820K | -391K | (13.2M) | -565K | (644K) | (1.2M) | (4.8M) | (3.6M) | (15.5M) | (6.6M) | |
-54.5M | -70.4M | -133.3M | -110.8M | -111M | -30.8M | -38.3M | -42M | -44.9M | -41.6M | -41M | -18.4M | -18.4M | -15.7M | -11.2M | -11.4M | -11.9M | -9M | -3.7M | -4.8M | |
1B | 796.2M | 702.8M | 680.3M | 366.8M | 517.5M | 498.8M | 369M | 355M | 184.6M | 171.9M | 208.8M | 188.4M | 227.1M | 211.1M | 73.8M | 191.8M | 166.5M | 119.8M | 132.9M | |
NET INCOME | ||||||||||||||||||||
(262.2M) | (184.7M) | (149.5M) | (124.1M) | (82.3M) | (120.7M) | (90.9M) | (64.3M) | (63.4M) | (74M) | (60.3M) | (73.8M) | (58.9M) | (67.1M) | (75M) | (22.6M) | (63.3M) | (55.8M) | (42.7M) | (51.8M) | |
785.1M | 614.6M | 378.2M | 107M | 243.9M | 397.4M | 407.7M | 304.1M | 290.9M | 110M | 110.8M | 135.1M | 129.4M | 160M | 136.1M | 51.3M | 128.5M | 110.7M | 77.1M | 82.2M |
STE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-K 10-K 2026 FY FY | May 29, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 06, 2026 | March 31, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | February 06, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 04, 2026 | February 04, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 07, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 06, 2025 | July 31, 2025 | 2025 |
Continue your STE research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.